Operator: Thank you. One moment for our next question. Our next question comes from the line of Roanna Ruiz from Leerink.
Roanna Ruiz: Hey, thanks for taking the follow-up. So I noticed on the call you also mentioned expanded field force, the new marketing and education campaign. I was curious, within that what are you doing to help educate new physician targets and new customers who might not yet have the deep experience with PYLARIFY yet? And how can you help drive their use through the year?
Paul Blanchfield: Very astute question, Roanna. We did expand the field force as we noted last year to be able to call on hospitals freestanding imaging centers, as well as referring physicians, namely neurologists which is largely in the staging indication, and referring oncologists, medical oncologists and radiation oncologist. We do see the vast majority of growth coming from existing prescribers. We do believe we made significant inroads in continuing to educate physicians on that benefit, but we really do this through an omni-channel approach that would be levering both, our medical team and appropriately at medical congresses where they get called into an answer questions that continue to be significant publications and discussions.
If you look at recent medical congresses, the number of posters that are discussing PSMA, both therapeutically and diagnostically, has significantly grown over the years. And so that first starts from a medical perspective to raise awareness appropriately. And then commercially, our sales teams are in their, in — in accounts, both at treating sites and referring physicians to raise awareness. We continue to gain new data and insights on our prescribing base which allows us to appropriately target those referring physicians. And then naturally, we do appropriate omni-channel marketing efforts, both in appropriate publications and other awareness, including appropriately within the patient segment. We really are seeing the fruits of that investment play out where we made increasing investments in the middle of last year, to really generate demand in addition to just cross-sell it.
We believe we appropriately invested ahead of the curve, and we believe as the clear market leader and largest voice in the marketplace, that we are having a disproportionate impact in driving the overall growth of the PSMA imaging market. And naturally as the market leader, we take a disproportionate benefit of those gains in the growth.
Operator: Thank you. One moment for our next question. Our next question comes to the line of Richard Newitter from Truist Securities.
Richard Newitter: Hi, excuse me. Thanks for the follow-up here. I just wanted to ask you, you mentioned lifecycle management on PYLARIFY. You kind of gave us a stay tuned on the future indication stats. I am just wondering what that means and looks like or if you can elaborate there? And also I asked this last quarter as well, but a competitor of yours is out there publicly talking about kind of — a PSMA PET diagnostic 2.0 version that could potentially restart the transitional pass-through clock for them while you’re still off pass-through, and potentially they’re still on. I’m just curious, do you have any insight on on how CMS views these — that type of effort? And is that something that you have in the works or could potentially replicate, if needed? Thank you.
Brian Markison: Yes Richard, thanks. A lot of good questions wrapped up into that. And I think we are holding our product improvements, lifecycle management strategies fairly close to the vest. Like you, we have listened to what other companies have said about their approach to a 2.0 and pass-through, and we have a particularly good knowledge of what needs to happen in order to make that work. So I’m not sure how much we want to elaborate. But Paul, I think, if you want you can add a little bit there.
Paul Blanchfield: Thanks, Rich. We very much understand the pathways that are being discussed out there in the marketplace, we have been aware of them. We believe just for context setting to be eligible for transitional pass-through based on current regulatory pathways and CMS requirements, you do need a new NDA; there are multiple paths to get there. Our team consistently monitors as Brian mentioned, developments in the industry. And we consider multiple options to support our ability to maintain patient access, and really maximize the value of the entire portfolio. We don’t feel the need to share our internal plans at this point publicly, and we will do so when appropriate. But overall, I think the key message for PYLARIFY right now is that we’re focused on delivering over $1 billion in sales for PYLARIFY this year making it the first ever PET imaging blockbuster, executing strategies including brand awareness, strategic partnerships with key customers that we’ve talked about, supporting CMS and congressional actions to mitigate that impact, and really expanding the market through our education efforts, as well as lifecycle management.
And we look forward to delivering on those and sharing more about some of the questions you asked when appropriate.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Andy Hsieh from William Blair.
Andy Hsieh: Thanks for allowing me to ask a second question. So, at the risk of sounding like an overly sensitive sell side analysts, you made a very interesting comment on the BD strategy, specifically focusing on radioligand. I just want to clarify, are you signaling a preference over other modalities such as antibodies or various peptide-based contracts as you survey the landscape?
Brian Markison: Well, I mean, I think at Lantheus we would naturally have a bias. But look, all royalties are coming of age, the ability to target the tumors more effectively with less off-target toxicity is really evolving, but it’s just another modality. And if you look at the overall market, it’s a small piece of the total cancer market. So — it’s emerging, it’s growing, it’s exciting, we’re seeing lots of valuations jump by big pharma paying a lot of attention to the space; so I guess you could say it’s validated from that perspective. But I mean — look, the simple truth is — the technology is proof to the point where you can really deliver a smarter bomb to the tumor with less toxic to the patient, and they can continue to go on and receive additional lines of therapy. So I think it’s exciting, it’s evolving, but it is — I can’t tell you, I have a preference but I certainly have a bias based on the business I’m in.
Operator: Thank you. Ladies and gentlemen, there are no further questions at this time. Thank you for participating in today’s conference. This concludes the program. You may disconnect and have a wonderful day.
